



Published in final edited form as:

*J Crit Care.* 2009 December ; 24(4): 568–574. doi:10.1016/j.jcrc.2009.05.015.

## A new dosing protocol reduces dexmedetomidine-associated hypotension in critically ill surgical patients<sup>\*,\*\*,\*</sup>

Anthony T. Gerlach, PharmD, BCPS<sup>a</sup>, Joseph F. Dasta, MS, FCCM<sup>b,c</sup>, Steven Steinberg, MD<sup>d</sup>, Larry C. Martin, MD<sup>e</sup>, and Charles H. Cook, MD, FCCM<sup>d</sup>

Anthony T. Gerlach: gerlach.6@osu.edu; Joseph F. Dasta: jdasta@mail.utexas.edu; Steven Steinberg: steven.steinberg@osumc.edu; Larry C. Martin: larry.martin@surgery.ufl.edu; Charles H. Cook: cook.131@osu.edu

<sup>a</sup>Department of Pharmacy, The Ohio State University Medical Center, Columbus, Ohio 43210, USA

<sup>b</sup>The Ohio State University, Columbus, Ohio, USA

<sup>c</sup>University of Texas, Round Rock, TX 78665, USA

<sup>d</sup>Department of Surgery, The Ohio State University Medical Center, Columbus, Ohio 43210, USA

<sup>e</sup>Department of Surgery, University of Florida, P.O. Box 100286, Gainesville, FL 32610, USA

### Abstract

**Background**—Although no ideal sedative exists, dexmedetomidine is unique because it produces sedation and analgesia without decreasing the respiratory drive. Hemodynamic responses to dexmedetomidine are variable and dependent on the patient population. Our initial experience was associated with an unacceptable incidence of hypotension and bradycardia. We evaluated occurrence of hypotension and bradycardia in critically ill surgical patients receiving dexmedetomidine before and after implementation of a dosing protocol.

**Methods**—This is a retrospective chart review of all admissions to a university medical center-based, 44-bed surgical intensive care unit pre and post protocol implementation.

**Results**—Forty-four patients received dexmedetomidine including 19 historic controls and 25 dosed via protocol. Both groups had comparable demographics and initial and maximum dosages of dexmedetomidine. Use of the dosing protocol resulted in fewer dosage changes (mean  $\pm$  standard deviation,  $4.8 \pm 3.8$  compared to  $7.8 \pm 3.9$ ;  $P = .014$ ) and fewer episodes of hypotension (16% vs 68.4%;  $P = .0006$ ) but did not influence bradycardic episodes (20% vs 15.5%;  $P > .99$ ).

**Conclusion**—We found that use of a protocol that increases the time interval between dosage adjustments may reduce dexmedetomidine-associated hypotension.

### Keywords

Dexmedetomidine; Intensive care unit; Hypotension

<sup>\*</sup>Joseph F. Dasta is a consultant and member of the Hospira Speakers Bureau for dexmedetomidine. None of the other authors have anything to disclose.

<sup>\*\*</sup>No outside finances were used to fund this study.

<sup>\*</sup>Author contributions—trial design: AG, SS, LM, CC; data collection: AG; data analysis: AG, SS, LM, CC.

© 2009 Elsevier Inc. All rights reserved.

Correspondence to: Anthony T. Gerlach, gerlach.6@osu.edu.

## 1. Introduction

After publication of *Too Err is Human: Building a Safer Health System* in 1999 by the Institute of Medicine, medication safety has become a top priority in health care [1]. That report focused on the observation that many medical errors involve medications and concluded that health care providers need to design safer systems [2,3]. Because of complexities of critical illness, patients in the intensive care unit (ICU) are considered to be at increased risk of medication errors and adverse drug events, particularly with intravenous medications [2–5]. Proposed strategies to improve medication safety in the ICU include intensivist-lead, multidisciplinary rounds with pharmacist participation; standardized drug preparation and administration; computerized prescriber order entry; bar coding technology; computerized intravenous infusion devices; education; and developing a culture of safety [2,6]. Because most medication errors and many adverse drug events are considered preventable, development of surveillance systems targeting strategies for improvement should help decrease adverse drug events in both the outpatient and the inpatient setting, including the ICU [6].

An essential part of ICU care is to protect patients from themselves during agitation, and this often requires use of sedatives such as propofol or benzodiazepines [7]. In addition, opioids are used to treat pain, a common contributor to agitation in surgical patients. Unfortunately, use of these medications is associated with adverse drug events such as respiratory depression, resulting in increased duration of mechanical ventilation, and development of ventilator-associated pneumonia, all of which increase ICU length of stay [8].

Dexmedetomidine is a sedative with a unique mechanism of action that became available in the United States in 1999 for sedation of critically ill patients [9]. Desirable properties of dexmedetomidine include induction of sedation and analgesia via stimulation of  $\alpha_2$ -receptors without concomitant respiratory depression by  $\gamma$ -aminobutyric acid-mimetic properties that accompany use of many other sedatives [9]. Additional advantages of dexmedetomidine include a relatively short half-life and hepatic metabolism [9]. Described adverse drug reactions with dexmedetomidine include altered blood pressure, nausea, and bradycardia [10,11]. Hypotension, which is the most commonly reported adverse effect, results from a sympatholytic effect mediated by activation of central  $\alpha_{2a}$ -receptors causing vasodilation [9,12]. Thus, dexmedetomidine has the desirable characteristic of inducing sedation without causing respiratory depression, but it also has potential side effects that might preclude its use during critical illness.

Despite an initial enthusiasm for dexmedetomidine to treat agitation in our surgical ICU, data from our drug surveillance monitoring system suggested an unacceptable incidence of hypotension and bradycardia associated with its use. Closer evaluation revealed that hypotension often occurred when dexmedetomidine dosage was titrated rapidly (more frequently than every 20 minutes) compared with slower rates of titration [13]. Based upon these data, a dosing protocol for dexmedetomidine was developed that allows titration no more frequently than every 30 minutes. In this report, we described reduced occurrence of hypotension associated with dexmedetomidine in our surgical ICU after institution of this dosing protocol.

## 2. Materials and methods

Dexmedetomidine was added to the Formulary of Accepted Medications at The Ohio State University Medical Center in 2001 and was restricted to use in the surgical ICU. We previously reported a medication use evaluation performance improvement project of patients receiving dexmedetomidine in the surgical ICU between October 2001 and December 2004 [13]. These data suggested that hypotension occurred more frequently when

*J Crit Care.* Author manuscript; available in PMC 2013 July 28.

dexmedetomidine is rapidly titrated. Based on these data, a dosing protocol was developed (Fig. 1). This protocol was reviewed and approved by the surgical ICU quality committee with representation from surgery, nursing, and pharmacy.

Between April 2005 and March 2006, patients received dexmedetomidine via this new protocol and were compared with historic controls that received dexmedetomidine rapidly titrated (<20 minutes between dosage adjustments) between October 2001 and December 2004. Patients were excluded if they were less than 18 or more than 89 years old, pregnant, incarcerated, or receiving vasopressors before initiation of dexmedetomidine. Data collected included demographics, Acute Physiology and Chronic Health Evaluation II (APACHE II) score on admission, sedation score, indication, dosage titration, length of therapy, time between dosing adjustments, and adverse drug reactions attributed to dexmedetomidine from start of infusion to end of infusion. Data were retrospectively collected from our electronic ICU charting system (CliniComp International, San Diego, Calif). Vitals signs can be automatically imported at the touch of a computer key with this system. The primary outcome was the occurrence of hypotension, defined as a mean arterial blood pressure less than 60 mm Hg attributed to dexmedetomidine, as determined by one of the investigators (AG). Development of bradycardia was also studied and defined as heart rate less than 50 beats per minute attributed to dexmedetomidine. Hemodynamic parameters were monitored for 2 hours before initiation of dexmedetomidine to 12 hours after discontinuation. Sedation scores (Ramsay Sedation Score was collected in the control group and Richmond Agitation Sedation Score [RASS] for the protocol group) were collected between 30 and 120 minutes of initiation and within 2 hours before or after the development of an adverse drug reaction [7,14]. To allow comparison between these different scales, patients are reported to be agitated, calm, or sedated. Our retrospective chart review received institutional review board exemption.

Statistical analysis was performed by Fisher exact test for nominal data or Student *t* test for continuous data. The Mann-Whitney *U* test was used for nonparametric data. Continuous data are presented as mean  $\pm$  standard deviation or median (25%–75% interquartile range). *P* values less than .05 were considered significant.

### 3. Results

Forty-four patients were included in analysis, including 25 patients that received dexmedetomidine after protocol institution and 19 historic controls that received rapidly titrated dexmedetomidine. Both groups had comparable demographics and admitting services (Tables 1 and 2). Median {25%–75% interquartile range} APACHE II scores upon admission were similar between groups (21 {15–25} protocol group vs 22 {15–29} historic control; *P* = .38). The mean duration of mechanical ventilation (protocol  $10.7 \pm 11.1$  days vs  $10.2 \pm 12.1$  days for controls; *P* = .89) and ICU length of stay (protocol  $14.5 \pm 11.1$  days, controls  $11.8 \pm 11.4$ ; *P* = .48) were similar between groups. Additional sedation was required in 8% of protocol patients (propofol in 1 patient with subarachnoid hemorrhage and lorazepam in 1 patient after trauma).

The mean initial dosage of dexmedetomidine ( $0.24 \pm 0.11 \mu\text{g kg}^{-1} \text{h}^{-1}$  protocol vs  $0.22 \pm 0.07 \mu\text{g kg}^{-1} \text{h}^{-1}$  controls; *P* = .42), the maximum dosage ( $0.43 \pm 0.19 \mu\text{g kg}^{-1} \text{h}^{-1}$  protocol vs  $0.54 \pm 0.16 \mu\text{g kg}^{-1} \text{h}^{-1}$  controls; *P* = .08), and time to maximal dosage ( $259 \pm 429$  minutes protocol vs  $153 \pm 150$  minutes controls; *P* = .4) were not statistically different between the groups (Table 2). Patients treated via protocol had significantly fewer dosage adjustments than historic control patients (protocol  $4.8 \pm 3.8$  vs  $7.8 \pm 3.9$  in controls; *P* = .014). Median durations of dexmedetomidine infusion were 19.2 {10.7–52.1} hours in the protocol group and 16.6 {7–33} hours in historic controls (*P* = .14). Sixteen patients

received dexmedetomidine longer than 24 hours (11/25 [25%] for protocol, 5/19 [26%] for historic controls;  $P = .34$ ). Two patients received loading infusions of dexmedetomidine, both historic controls ( $P = .19$ ).

Seventeen patients developed hypotension, but this occurred significantly less frequently in protocol patients compared with historic controls (4 [16%] vs 13 [68.4%];  $P = .0006$ ). Bradycardia was not significantly different between groups (5 [20%] vs 3 [15.8%];  $P > .99$ ). A total of 22 patients developed hypotension and/or bradycardia (6 [24%] in the protocol group vs 16 [84%] in the historic controls;  $P = .0002$ ) including 3 patients developing both (2 [8%] in the protocol group and 1 [5.3%] of the controls;  $P > .99$ ). The total number of adverse drug reactions was significantly less in patients treated via protocol (7 [28%] vs 15 [78.9%];  $P = .0019$ ) than historic controls. For patients that developed hypotension, there was no statistical difference in mean arterial pressure between groups (mean nadir mean arterial pressure  $51.8 \pm 2.2$  mm Hg protocol group vs  $51.1 \pm 7.6$  mm Hg for historic controls;  $P = .87$ ), and the mean nadir heart rates were similar for those that developed bradycardia ( $39.3 \pm 9.9$  beats per minutes for historic controls vs  $37.8 \pm 9.9$  for controls). Time from initiation of therapy to development of hypotension was similar between protocol and historic control groups ( $4.2 \pm 3.6$  vs  $3.8 \pm 2.8$  hours, respectively;  $P = .84$ ) as was the time from initiation of therapy to bradycardia ( $12 \pm 9.2$  vs  $5.9 \pm 3.6$  hours;  $P = .32$ ). Hypotension ( $3.9 \pm 3$  hours) tended to occur before bradycardia ( $9.7 \pm 7.9$  hours) in all patients, but this difference did not reach significance ( $P = .059$ ). Only 2 of the 17 patients that developed hypotension had received dexmedetomidine for more than 24 hours ( $P > .99$ ). For patients developing hypotension or bradycardia, all but 1 case were treated by stopping the dexmedetomidine infusion. In addition, hypotension was treated with administration of intravenous fluids in 5 patients (1 protocol patient and 4 historic controls). Four historic control patients required transient vasopressors, and 2 patients received atropine (1 in each group;  $P > .99$ ).

The level of sedation or agitation 30 to 120 minutes after dexmedetomidine initiation was documented in 41 patients (24 [96%] protocol vs 17 [89.5%] historic controls;  $P = .57$ ) and within 2 hours of the development of an adverse effect in all but 1 patient in the control group (Table 3). In the first hours of sedation, the median sedation scores {25%–75% interquartile range} for both groups were calm (median RASS was 0 {–2,1} for the protocol group and median Ramsay Sedation Score was 2 {1,3} for the historical controls). Around the time of development of hypotension and bradycardia, the median RASS in the protocol group was lightly sedated (–1 {–3,1}), and the median Ramsay Sedation Score for the historic controls was calm (2 {1,3}). The mean time from development of an adverse effect and documentation of sedation levels was  $0.74 \pm 0.7$  hours.

#### 4. Discussion

This study suggests that occurrence of hypotension associated with dexmedetomidine use in postoperative ICU patients can be significantly reduced by implementation of a dosing protocol. Although hypotension is a potential adverse effect of any sedative agent [15–22], our initial experience with dexmedetomidine showed a somewhat higher incidence of hypotension (approximately 69%) than reported by others (Table 4) [16,17,23]. Some have suggested that dexmedetomidine-associated hypotension and bradycardia are consequent to activation of  $\alpha_2$ -receptors resulting in sympatholysis [11,15,17], and others have reported that administration of dexmedetomidine without loading infusions can achieve satisfactory sedation [21,23]. We chose a slightly different approach, which was to slow down the rate of titration, and report that our protocol may reduce dexmedetomidine-associated hypotension to levels lower than previously reported (16%) [13,16,17,23].

Although the cause is not known for certain, there are several possible mechanisms for development of dexmedetomidine-associated hypotension, especially in patients receiving rapid dosage titration. The first is an opposing effect on  $\alpha_{2a}$  and  $\alpha_{2b}$  receptors. Work by others has shown that heart rate, cardiac output, and norepinephrine concentrations decrease progressively with increasing dexmedetomidine concentrations, but dexmedetomidine causes a biphasic change in blood pressure [24]. At low concentrations ( $<1.9$  ng/mL), mean arterial pressure decreases, followed by increasing mean arterial pressures observed with increasing dexmedetomidine concentrations [24]. It is thought that activation of peripheral  $\alpha_{2b}$ -receptors at higher concentrations causes vasoconstriction, thereby offsetting the vasodilation from activation of  $\alpha_{2a}$ -receptors. Critically ill patients receiving a maximum dosage of  $0.7 \mu\text{g kg}^{-1} \text{h}^{-1}$  have demonstrated peak serum dexmedetomidine concentrations of  $1.2$  ng/mL with a range of  $0.71$ – $1.7$  ng/mL [25]. This is below the point where the activation of  $\alpha_{2b}$  starts to predominate and may explain why hypotension is the most common adverse effect.

A second possible mechanism contributing to hypotension induced by dexmedetomidine relates to its pharmaco-kinetic properties. Dexmedetomidine requires extensive metabolism by the liver but appears to have minimal interaction with the cytochrome p450 enzymes [10,11]. Dexmedetomidine exhibits linear pharmacokinetics with distribution ( $\alpha$ ) half-life range of 6.0 to 8.6 minutes and elimination ( $\beta$ ) half-life of approximately 2 to 3.1 hours in both healthy volunteers and critically ill patients [10,11,25]. Thus, completion of distribution from the central to peripheral compartments requires approximately 30 to 45 minutes, whereas steady-state drug concentrations do not occur until approximately 10 to 15 hours. Rapid titration (sooner than every 20–30 minutes) therefore provides additional drug before distribution of the previous dose is complete. This could therefore result in drug accumulation in the central compartment with development of hypotension after completion of distribution. There was a trend toward lower mean maximum dosage in the protocol group ( $0.43 \pm 0.02$  vs  $0.54 \pm 0.16 \mu\text{g kg}^{-1} \text{h}^{-1}$ ;  $P = .08$ ). Because we did not measure dexmedetomidine serum concentrations, this remains a hypothesis consistent with our clinical data that can be tested in future studies.

The optimal method to safely titrate dexmedetomidine in critically ill patients has not been definitively established, but available data support the practice of slower titration. Timing of dexmedetomidine titration has only been described in 2 studies of critically ill patients: one in adults and one in children [26,27]. In adult ICU patients receiving dexmedetomidine longer than 24 hours (median, 71.5 hours), dexmedetomidine was titrated no sooner than every 15 minutes [26]. Mean systolic blood pressures decreased approximately 16% within 2 to 4 hours of initiating therapy, and the lowest single systolic blood pressure was reported 12 hours after starting therapy. Beyond 12 hours (presumably at/near steady state), systolic blood pressures showed minimal change ( $\pm 10\%$ ) during dexmedetomidine infusion. In pediatric ICU patients (median age, 5 months) receiving dexmedetomidine without loading infusions titrated with changes more than 1 hour apart, there were no episodes of dexmedetomidine-associated hypotension [27]. One patient (6%) developed hypotension when dexmedetomidine was titrated less than 1 hour after the previous change. Thus, these studies taken together with the current study suggest that a slow titration may minimize the incidence of hypotension; once again, further studies are needed to confirm.

The optimal dosage and dosing titration frequency that balance safety and efficacy are also unknown. Dexmedetomidine was approved for use in the United States, based on 2 randomized, double-blind, placebo-controlled trials with the maximum dosage of  $0.7 \mu\text{g kg}^{-1} \text{h}^{-1}$  [9,16]. In our study, the maximum dosage of dexmedetomidine was also  $0.7 \mu\text{g kg}^{-1} \text{h}^{-1}$ , although many studies have reported higher dosages [9]. The revised labeling for procedures or surgery in nonintubated patients increases the maximal dosage to  $1.0 \mu\text{g kg}^{-1}$

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.